NS2330 · triple monoamine reuptake inhibitor
Tesofensine
Small molecule Not a peptide
What it is
Tesofensine is an oral small molecule, not a peptide. It inhibits reuptake of dopamine, norepinephrine, and serotonin and was studied for weight loss after CNS programs.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- Not a peptide. Triple monoamine reuptake inhibitor once in obesity trials.
- Appetite suppression via brain chemistry more like older diet drugs than like GLP-1.
- Heart rate and CNS side effects are why it never became a simple OTC.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Central appetite suppression via monoamine tone, closer to older weight-loss stimulants than to GLP-1 receptor agonists.
Possible side effects / caveats
Heart rate, blood pressure, insomnia, dry mouth, and mood/anxiety effects. This is not a gentle metabolic peptide.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Trial range (historical obesity work) | About 0.25–1 mg daily | Oral once daily | Order of magnitude from published trials |